SCHEMBL398286

SCHEMBL398286

NC(=O)CC[C@H](N)C(=O)OCCO

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.52
BLM P54132 1/20 0.52
PMP22 Q01453 1/20 0.52
KMT2A Q03164 1/20 0.52
DPP4 P27487 1/20 0.39
DPP8 Q6V1X1 1/20 0.39
DPP9 Q86TI2 1/20 0.39
GRM8 O00222 1/20 0.34
GRM6 O15303 1/20 0.34
GRIN2D O15399 1/20 0.34
GRIN3B O60391 1/20 0.34
GSR P00390 1/20 0.34
CYP1A2 P05177 1/20 0.34
GRIK1 P39086 1/20 0.34
GRM5 P41594 1/20 0.34
GRIA1 P42261 1/20 0.34
GRIA2 P42262 1/20 0.34
GRIA3 P42263 1/20 0.34
SLC1A3 P43003 1/20 0.34
SLC1A2 P43004 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4465007 0.89 ALOX15 (0.48) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL8009500 0.88 ALOX15 (0.56) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL5424018 0.84 GRM8 (0.54) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL7541045 0.84 MGLL (0.36) ALOX15BLMPMP22KMT2AGRM8
SCHEMBL5424016 0.84 MGLL (0.36) ALOX15BLMPMP22KMT2AGRM8
SCHEMBL8998302 0.83 TSHR (0.38) GRM8GRM6GRIN2DGRIN3BGSR
SCHEMBL2305262 0.82 ALOX15 (0.50) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL28643800 0.82 KMT2A (0.50) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL8581073 0.79 NOD1 (0.49) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL8749113 0.79 NOD1 (0.49) ALOX15BLMPMP22KMT2ADPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118680883-A Loadable porous structure for use as an implant 瑞艾克斯制药公司 2024-09-24 CN claimed
US-8354455-B2 Prodrugs containing novel bio-cleavable linkers Piramal Enterprises Limited and Apparao Satyam (IN) 2013-01-15 US claimed
WO-2013004716-A1 PEPTIDE BEADS UNIVERSITÄT BASEL (CH) 2013-01-10 WO claimed
US-20110274695-A1 PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS PIRAMAL LIFE SCIENCES LIMITED 2011-11-10 US claimed
EP-2266625-A2 Prodrugs Containing Novel Bio-Cleavable Linkers Piramal Life Sciences Limited (IN) 2010-12-29 EP claimed
US-20100081710-A1 Modified L-Nucleic Acid NOXXON PHARMA AG (DE) 2010-04-01 US claimed
EP-2075011-A2 Prodrugs Containing Bio-Cleavable Linkers Piramal Life Sciences Limited (IN) 2009-07-01 EP claimed
JP-2008510795-A 2008-04-10 JP claimed
US-20070196275-A1 Diagnostic Imaging Compositions, Their Methods Of Synthesis And Use NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2007-08-23 US claimed
EP-1789091-A2 PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS Nicholas Piramal India Limited (IN) 2007-05-30 EP claimed
EP-1389090-A2 DIAGNOSTIC IMAGING COMPOSITIONS, THEIR METHODS OF SYNTHESIS AND USE Board of Regents, The University of Texas System (US) 2004-02-18 EP claimed
US-20030073615-A1 Water soluble paclitaxel derivatives CELL THERAPEUTICS, INC. 2003-04-17 US claimed
US-20030003048-A1 Diagnostic imaging compositions, their methods of synthesis and use NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-01-02 US claimed
WO-2002087498-A2 DIAGNOSTIC IMAGING COMPOSITIONS, THEIR METHODS OF SYNTHESIS AND USE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-11-07 WO claimed
EP-0932399-A4 WATER SOLUBLE PACLITAXEL PRODRUGS PG TXL CO LP (US) 2002-10-24 EP claimed
US-20010034363-A1 WATER SOLUBLE PACLITAXEL DERIVATIVES PG-TXL COMPANY, L.P. 2001-10-25 US claimed
JP-2000507930-A 2000-06-27 JP claimed
US-5977163-A Water soluble paclitaxel prodrugs PG-TXL COMPANY, L. P. (US) 1999-11-02 US claimed
EP-0932399-A1 WATER SOLUBLE PACLITAXEL PRODRUGS PG-TXL Company, L.P. (US) 1999-08-04 EP claimed
WO-1997033552-A1 WATER SOLUBLE PACLITAXEL PRODRUGS PG-TXL COMPANY, L.P. (US) 1997-09-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110274695-A1 PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS SI, UGT1A1, CYP2B6 ALOX15 1077/4885BLM 2982/4885PMP22 3529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.